Hnp Capital LLC Regeneron Pharmaceuticals, Inc. Transaction History

Hnp Capital LLC

$356 Million
Q1 2023

A detailed history of Hnp Capital LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Hnp Capital LLC holds 1,118 shares of REGN stock, worth $1.29 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares

1,118

Previous 1,142 2.1%

Holding current value

$1.29 Million

Previous $823,000 11.54%

% of portfolio

0.26%

Previous 0.23%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 18, 2023	SELL	$680.49 - $826.97 $16,331 - $19,847	-24 Reduced 2.1%	1,118 $918,000
Q4 2022 Jan 24, 2023	SELL	$705.89 - $766.39 $21,882 - $23,758	-31 Reduced 2.64%	1,142 $0
Q3 2022 Oct 18, 2022	SELL	$573.97 - $724.32 $12,053 - $15,210	-21 Reduced 1.76%	1,173 $808,000
Q2 2022 Jul 20, 2022	SELL	$548.35 - $738.84 $13,708 - $18,471	-25 Reduced 2.05%	1,194 $706,000
Q1 2022 Aug 15, 2022	BUY	$595.12 - $698.43 $725,451 - $851,386	1,219 New	1,219 $851,000
Q1 2022 May 02, 2022	SELL	$595.12 - $698.43 $761,158 - $893,291	-1,279 Closed	0 $0
Q4 2021 Jan 18, 2022	BUY	$543.48 - $670.97 $20,108 - $24,825	37 Added 2.98%	1,279 $808,000
Q3 2021 Oct 14, 2021	BUY	$574.03 - $680.96 $17,220 - $20,428	30 Added 2.48%	1,242 $752,000
Q2 2021 Jul 14, 2021	BUY	$472.8 - $558.54 $20,330 - $24,017	43 Added 3.68%	1,212 $677,000
Q1 2021 May 28, 2021	BUY	$446.73 - $548.2 $522,227 - $640,845	1,169 New	1,169 $553,000
Q2 2020 Jul 06, 2020	SELL	$493.32 - $643.92 $189,434 - $247,265	-384 Closed	0 $0
Q1 2020 Apr 22, 2020	BUY	$336.18 - $494.43 $129,093 - $189,861	384 New	384 $187,000

Others Institutions Holding REGN

# of Institutions

1,461

Shares Held

84.5M

Call Options Held

907K

Put Options Held

1.3M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $124B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hnp Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hnp Capital LLC with notifications on news.

Account